ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Specialty Chemicals

Arena licenses heart drug ralinepag to United Therapeutics

by Michael McCoy
November 18, 2018 | APPEARED IN VOLUME 96, ISSUE 46

 

Arena Pharmaceuticals has agreed to license ralinepag, a small-molecule treatment for pulmonary arterial hypertension (PAH), to United Therapeutics for $800 million plus up to $400 million in milestone payments. The drug, discovered by Arena scientists and now in Phase III clinical trials, is a prostacyclin receptor ­agonist that inhibits platelet aggregation and proliferation of vascular smooth muscle cells. United Therapeutics already markets a number of PAH treatments, including Adcirca, Orenitram, and Remodulin.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment